Animal Pharmacokinetic/Pharmacodynamic Studies (APPS) Reporting Guidelines
- 162 Downloads
Animal pharmacokinetic/pharmacodynamic studies are commonly used to provide meaningful preclinical information that can be utilized by the scientific community to conduct first-in-human studies. Poor presentation and interpretation of the data limit study reproducibility, and may result in rejection when the study is submitted to a journal, leading to loss of time and resources at multiple levels. In addition, inconsistencies in reporting the results of animal studies may limit the ability to extrapolate the experimental findings to humans. A few guidelines have been published to make the reporting of animal studies consistent; however, strict implementation of these guidelines by authors, reviewers, and journal editors is still lacking. In an attempt to make the reporting of animal pharmacokinetic/pharmacodynamic studies consistent and improve the standard of reporting, this article provides guidelines that can be followed when submitting such studies to a journal. A detailed checklist, based on these guidelines, has been developed that can be used by the authors, reviewers, and editors to check if the required information is included in the manuscript. These guidelines can also be used for designing and performing such studies.
Compliance with Ethical Standards
No external source of funding was used to prepare this article.
Conflict of interest
Jasbir Singh is the Editor-in-Chief of European Journal of Drug Metabolism and Pharmacokinetics and a salaried employee of Adis International Limited. He has no other conflicts of interest to declare. Fawzy Elbarbry, Ke Lan, and Tomasz Grabowski have no conflicts of interest to declare. The Editor in Chief of the European Journal of Drug Metabolism and Pharmacokinetics was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
- 8.International Committee of Medical Journal Editors. Preparing for submission. ICMJE. 2017. http://www.icmje.org/recommendations/browse/manuscript-preparation/preparing-for-submission.html#b. Accessed 17 May 2017.
- 11.ICH. Statistical principles for clinical trials e9. 1998. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf. Accessed 9 May 2017.
- 14.Robinson K. GLPs and the importance of standard operating procedures. BioPharm International. 2003. http://www.biopharminternational.com/glps-and-importance-standard-operating-procedures. Accessed 26 Sept 2017.
- 16.US FDA. Comparison chart of FDA and EPA good laboratory practice (GLP) regulations and the OECD principles of GLP. 2004. https://www.fda.gov/downloads/ICECI/EnforcementActions/BioresearchMonitoring/UCM133724.pdf. Accessed 8 May 2016.
- 17.NC3Rs. The 3Rs. The National Centre for the Replacement, Refinement and Reduction of Animals in Research. https://www.nc3rs.org.uk/the-3rs. Accessed 10 Nov 2017.
- 18.Mojiminiyi FB, Anibogu CN, Sofola AO, Adigun SA. Endothelium-dependent and -independent relaxations in aortic rings obtained from hypertensive hooded (Aguti) rats. Niger J Physiol Sci. 2007;22(1–2):109–16.Google Scholar
- 20.ICH. Guidance for industry. S6 addendum to preclinical safety evaluation of biotechnology-derived pharmaceuticals. 2012. https://www.fda.gov/downloads/Drugs/…/Guidances/UCM194490.pdf. Accessed 8 May 2017.
- 21.OECD. Test No. 417: toxicokinetics. OECD guidelines for the testing of chemicals. 2010. http://www.keepeek.com/Digital-Asset-Management/oecd/environment/test-no-417-toxicokinetics_9789264070882-en#.WQ92YkWGPcs. Accessed 8 May 2016.
- 22.EC. Commission implementing decision of 14 November 2012 establishing a common format for the submission of the information pursuant to Directive 2010/63/EU of the European Parliament and of the Council on the protection of animals used for scientific purposes. 2012. http://ec.europa.eu/environment/chemicals/lab_animals/pdf/Unofficial%20Consolidated%20version.pdf. Accessed 8 May 2016.
- 25.EC. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes 2010. http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L:2010:276:FULL&from=EN. Accessed 8 May 2016.
- 26.EMA. Guideline on regulatory acceptance of 3R (replacement, 6 reduction, refinement) testing approaches. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500174977.pdf. Accessed 8 May 2010.
- 27.Baker DG, Lipman NS. Factors that can influence animal research. In: Fox J, Anderson L, Otto G, Pritchett-Corning K, Whary M, editors. Laboratory animal medicine, 3rd ed. London: Academic; 2015. p. 1441–95.Google Scholar
- 32.Chow SC, Liu JP. Experimental design principles for animal studies in pharmaceutical development. In: Chow SC, Liu JP, editors. Design and analysis of animal studies in pharmaceutical development. New York: Dekker; 1998.Google Scholar
- 37.EMA. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003616.pdf. Accessed 8 May 2017.
- 40.US FDA. Guidance for industry. Content and format of effectiveness and target animal safety technical sections and final study reports for submission to the division of therapeutic drugs for non-food animals. 2001. https://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM052645.pdf. Accessed 8 May 2017.
- 41.US FDA. Product development under the animal rule. Guidance for Industry. 2015. https://www.fda.gov/downloads/drugs/guidances/ucm399217.pdf. Accessed 8 May 2016.
- 42.US FDA. Guidance for industry. Protocol development guideline for clinical effectiveness and target animal safety trials. 2001. https://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm052372.pdf. Accessed 8 May 2017.
- 43.EMA. Guideline on the investigation of bioequivalence. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf. Accessed 8 May 2016.
- 44.US FDA. Guidance for industry. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. 2013. https://www.fda.gov/downloads/drugs/guidances/ucm377465.pdf. Accessed 8 May 2017.
- 46.OECD. OECD series on principles of GLP and compliance monitoring. 1999. http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?doclanguage=en&cote=env/jm/mono(99)22. Accessed 8 May 2017.
- 47.US FDA. Guidance for industry and other stakeholders toxicological principles for the safety assessment of food ingredients. 2007. https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm. Accessed 8 May 2017.
- 49.EMA. Routes of administration controlled vocabulary. 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002730.pdf. Accessed 8 May 2017.
- 50.US FDA. Guidance for industry. Population pharmacokinetics. 1999. https://www.fda.gov/downloads/drugs/guidances/UCM072137.pdf. Accessed 8 May 2017.
- 51.NC3Rs. Blood sampling. 2017. https://www.nc3rs.org.uk/3rs-resources/blood-sampling. Accessed 8 May 2017.
- 53.US FDA. Guidance for industry. Exposure–response relationships—study design, data analysis, and regulatory applications. 2003. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072109.pdf. Accessed 8 May 2017.
- 55.EMA. Guideline on bioanalytical method validation. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf. Accessed 16 May 2017.
- 56.US FDA. Guidance for industry: Bioanalytical method validation. 2013. https://www.fda.gov/downloads/Drugs/Guidances/ucm368107.pdf. Accessed 8 May 2017.
- 57.EMA. Guideline on reporting the results of population pharmacokinetic analyses. 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003067.pdf. Accessed 9 May 2017.
- 58.EMA. Guideline on non-clinical local tolerance testing of medicinal products. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/11/WC500197321.pdf. Accessed 8 May 2017.
- 61.International Committee of Medical Journal Editors. Defining the role of authors and contributors. ICMJE. 2017. http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html. Accessed 17 May 2017.
- 62.Springer. Reference styles. Springer. 2017. https://www.springer.com/gp/authors-editors/book-authors-editors/manuscript-preparation/5636. Accessed 17 May 2017.
- 64.Guillen J. Laboratory animals: regulations and recommendations for global collaborative research. Cambridge: Academic; 2013.Google Scholar
- 65.European Commission. Ban on animal testing. 2018. https://ec.europa.eu/growth/sectors/cosmetics/animal-testing_en. Accessed 1 May 2018.